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Aims: We evaluated the impact of relevant patient-level characteristics on the efficacy and 
safety of subcutaneous, once-weekly semaglutide in subjects with T2D.  
Materials and Methods: Exploratory post hoc analyses of pooled SUSTAIN 1–5 (phase 3a) 
randomized, controlled trials examined the change from baseline in HbA1c and body weight 
(BW), and the proportions of subjects achieving the composite endpoint (HbA1c <7.0% [53 
mmol/mol], without weight gain or severe/blood glucose-confirmed symptomatic 
hypoglycaemia) at week 30 with semaglutide (0.5/1.0 mg) across clinically relevant patient 
subgroups: baseline HbA1c  (≤7.5, >7.5–8.0, >8.0–8.5, >8.5–9.0 and >9.0%), background 
medications, diabetes duration and pancreatic beta-cell function. 
Results: Mean HbA1c (%-point) reductions increased from lowest to highest HbA1c 
subgroups (–0.9, –1.2,–1.5, –1.7 and –2.3% [effect of subgroup within treatment: 
p=0.247] for semaglutide 0.5 mg, and –1.1, –1.4, –1.9, –2.1 and –2.7% [p=0.045] for 
semaglutide 1.0 mg), with mean HbA1c ranges at week 30 of 6.3–7.3% and 6.1–6.9%, 
respectively. The corresponding BW reductions generally decreased with increasing baseline 
HbA1c (–4.4, –3.9, –3.9, –3.3 and –2.9 kg [p=0.004], and –6.4, –5.9, –5.2, –4.5 and –4.8 
kg [p<0.001], respectively). HbA1c and BW reductions were consistently greater for 
semaglutide 1.0 mg versus 0.5 mg across background medication, diabetes duration and 
pancreatic beta-cell function subgroups. Adverse events with semaglutide were consistent 
with the GLP-1RA class, with gastrointestinal events the most common.   
Conclusions: Semaglutide was consistently efficacious across the continuum of diabetes 





Current guidelines for type 2 diabetes (T2D) management prioritize the use of glucagon-like 
peptide-1 receptor agonists (GLP-1RAs) in specific populations and as first injectable 
therapy before insulin.1,2 The emphasis is on patient-centred care and individualized 
treatment, including consideration of patients' clinical characteristics and comorbidities.1,2 
Clinical indicators of disease status in heterogeneous populations of adults with T2D, 
including glycaemic control (HbA1c), duration of disease, background antidiabetes 
medications and pancreatic beta-cell function, may impact the efficacy and safety of GLP-
1RA therapy. An in-depth evaluation of patient subgroups provides insight into whether 
distinct populations respond differently, and further guides individualization of therapy. 
Semaglutide (Novo Nordisk, Bagsværd, Denmark) is a subcutaneous (s.c.), once-weekly 
(OW) GLP-1 analogue for the treatment of T2D,3,4 the efficacy and safety of which has been 
established in the global phase 3a and 3b SUSTAIN (Semaglutide Unabated Sustainability in 
Treatment of Type 2 Diabetes) clinical trial development programme.5-11 Semaglutide s.c. 
OW demonstrated superior reductions in HbA1c and body weight (BW) compared with 
placebo and active comparators.5-9 The SUSTAIN 1−5 trials (n=3,918) represented the full 
continuum of diabetes care, including treatment-naïve subjects, those on a background of 
oral antidiabetes drugs (OADs;) and on insulin, with differences in baseline characteristics.5-
9 
The present post hoc exploratory analyses of data from the SUSTAIN trials aimed to assess 
the impact of clinical indicators of disease status (baseline HbA1c, background antidiabetes 
medications, diabetes duration and pancreatic beta-cell function) on the efficacy and safety 
of semaglutide s.c. OW in subjects with inadequately controlled T2D.  
 
2 Materials and Methods 
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2.1 Individual trial designs  
The phase 3a, multinational, randomized, controlled SUSTAIN 1–5 trials compared 
semaglutide s.c. OW (0.5 mg and/or 1.0 mg) with placebo (SUSTAIN 1, monotherapy; 
SUSTAIN 5, add-on to basal insulin) or active comparators (SUSTAIN 2, sitagliptin 100 mg; 
SUSTAIN 3, exenatide extended-release 2.0 mg; SUSTAIN 4, insulin glargine titrated-to-
target) in subjects with inadequately controlled T2D (comparator data not included in this 
post hoc analysis) over 30 weeks (SUSTAIN 1, 4 and 5) or 56 weeks (SUSTAIN 2 and 3). 
The trials have been previously published (Table 1).5-9 
2.2 Patient population 
Key inclusion and exclusion criteria were similar across the SUSTAIN 1–5 trials.5-9 Briefly, 
adult subjects (≥18 years) with T2D (HbA1c: ≥7.0–10.0% [53–86 mmol/mol] for SUSTAIN 
1, 4 and 5 or ≥7.0–10.5% [53–91 mmol/mol] for SUSTAIN 2 and 3) and an estimated 
glomerular filtration rate of ≥30 mL/min/1.73 m2 (SUSTAIN 1, 4 and 5) or ≥60 
mL/min/1.73 m2 (SUSTAIN 2 and 3) were eligible for inclusion.  
All trials were registered with ClinicalTrials.gov (NCT02054897, NCT01930188, 
NCT01885208, NCT02128932 and NCT02305381) and conducted according to the 
International Conference on Harmonisation Good Clinical Practice guidelines12 and the 
Declaration of Helsinki.13 Trial protocols were approved by the institutional review boards 
and ethics committees at participating centres. Subjects provided written informed consent 
before trial-related activities commenced. 
2.3 Subgroup analyses 
Key indicators of disease status were selected for post hoc analyses: baseline HbA1c, 




For baseline HbA1c analyses, subjects were divided into HbA1c categories (≤7.5% [≤58 
mmol/mol], >7.5–8.0% [>58–64 mmol/mol], >8.0–8.5% [>64–69 mmol/mol], >8.5%–
9.0% [>69–75 mmol/mol] and >9.0% [>75 mmol/mol]). For diabetes duration analyses, 
diabetes duration categories (≤5 years, >5–10 years and >10 years) were assessed. Both 
HbA1c and diabetes duration subgroup analyses used pooled SUSTAIN 1–5 data. Categories 
for HbA1c and diabetes duration analyses were selected based on clinical relevance, with 
HbA1c categories also reflecting the targets utilised in current clinical guidelines for diabetes 
management.1,2,14 
Supporting the diabetes duration analyses, pancreatic beta-cell function (glucose-stimulated 
insulin secretion) was assessed using the homeostatic model assessment of beta-cell 
function (HOMA-B),15,16  including pooled data from SUSTAIN 1–3 only (HOMA-B cannot be 
applied in subjects taking exogenous insulin, as in SUSTAIN 4 (insulin glargine comparator) 
and 5 (add-on to basal insulin).16 No specific thresholds for beta-cell function were used and 
subjects were categorized into HOMA-B tertiles: low (≤27.21%), intermediate (>27.21 to 
51.71%) and high (>51.71%) endogenous beta-cell function. 
For background antidiabetes medication analyses, subjects were divided into subgroups (no 
background medication, metformin monotherapy, other OADs and basal insulin ± 
metformin). There were differences in background medications across trials: semaglutide 
was assessed in drug-naïve subjects (SUSTAIN 1); as add-on to existing stable background 
antidiabetes treatments (metformin, thiazolidinedione or both [SUSTAIN 2]; maximum two 
of metformin, thiazolidinedione and/or sulphonylurea [SUSTAIN 3]; metformin ± 
sulphonylurea [SUSTAIN 4]); and as add-on to basal insulin ± metformin (SUSTAIN 5). 
Pooled SUSTAIN 2–4 data were used for the ‘metformin monotherapy’ and ‘other OADs’ 
subgroups; data by trial was used for ‘no background medication’ (SUSTAIN 1) and for 
‘basal insulin ± metformin’ (SUSTAIN 5).  
2.4 Endpoints and assessments  
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Efficacy endpoints were similar across all trials in the pre-planned analyses; the primary and 
secondary confirmatory endpoints were change in HbA1c (%-point, hereafter referred to as 
%) and BW (kg), respectively, from baseline to end of treatment. Week 30 was the latest, 
common ‘on treatment’ time point across the SUSTAIN 1–5 trials and was selected as cut-
off for these analyses, allowing for inter-trial comparisons. Supportive secondary endpoints 
included subjects achieving a triple composite endpoint of HbA1c <7.0% (<53 mmol/mol) 
without weight gain or severe (according to the American Diabetes Association [ADA] 
classification)17 or blood glucose (BG)-confirmed symptomatic hypoglycaemia (plasma 
glucose <3.1 mmol/L [56 mg/dL] with symptoms consistent with hypoglycaemia).5-9  
Safety was assessed as the numbers of adverse events (AEs), serious AEs and AEs leading 
to premature treatment discontinuation in the subgroups within each treatment group. 
Specific AEs of clinical interest analysed included gastrointestinal disorders and 
hypoglycaemic events. 
2.5 Statistical analyses  
Post hoc analyses were performed using pooled or by trial data as described in section 2.3. 
Efficacy analyses included ‘on-treatment without rescue medication’ data from all subjects 
contributing to the full analysis sets (randomized and exposed to at least one dose of the 
trial product) across the SUSTAIN 1–5 trials. Change from baseline analyses were adjusted 
for trial, country, treatment, baseline value and subgroup, using mixed model for repeated 
measurements (MMRM) imputations for missing data. Interaction effects were included for 
country and baseline value by trial and subgroup by treatment. Outcome values are 
presented as mean (standard error) for each of the categories analysed, unless otherwise 
stated. The proportions of subjects achieving the composite endpoint (HbA1c <7.0% [<53 
mmol/mol], without weight gain or severe/BG-confirmed symptomatic hypoglycaemia) were 
based on observed data and MMRM imputations for subjects with missing data. 
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The safety analysis set included data from subjects who were exposed to at least one dose 
of semaglutide and based on ‘on treatment’ data. The proportions of subjects experiencing 
at least one AE were adjusted per trial using the Cochran–Mantel–Haenszel method. 
 
3 Results 
3.1 Subject disposition and baseline characteristics 
Of the 3,918 subjects with T2D who were randomized to subcutaneous, once-weekly 
semaglutide or comparator treatment in the SUSTAIN 1–5 trials, 2,465 were assigned to 
semaglutide and received at least one dose of the trial medication (0.5 mg, n=1,031 and 
1.0 mg, n=1,434). Baseline characteristics by trial and treatment group (Table 1) and 
according to each subgroup analysis (Supplementary Table 1) were broadly similar, with 
differences reflecting trial eligibility criteria and heterogeneity of the population with respect 
to the continuum of T2D care. 
3.2 Efficacy by subgroup  
3.2.1 Effect by baseline HbA1c (SUSTAIN 1─5 pooled) 
Overall, the magnitude of the reductions in HbA1c were greater in subgroups with higher 
baseline HbA1c levels for both semaglutide 0.5 mg and 1.0 mg (Figure 1A). Reductions in 
HbA1c for semaglutide 0.5 mg ranged from –0.9% (baseline HbA1c ≤7.5%) to –2.3% 
(baseline HbA1c >9.0%), and for semaglutide 1.0 mg ranged from –1.1% (baseline HbA1c 
≤7.5%) to –2.7% (baseline HbA1c >9.0%). There was a significant effect of the HbA1c 
subgroup within treatment for semaglutide 1.0 mg (p=0.045), but not 0.5 mg (p=0.247)  
Similar HbA1c concentrations were achieved in all HbA1c subgroup categories, with estimated 
mean HbA1c levels at week 30 close to or less than 7.0% (53 mmol/mol).  
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Conversely, the magnitude of the reductions in body weight were generally lower in 
subgroups with higher baseline HbA1c (Figure 1B). Reductions in body weight from baseline 
to week 30 were observed across all baseline HbA1c subgroups, ranging from –2.9 kg 
(baseline HbA1c >9.0%) to –4.4 kg (baseline HbA1c ≤7.5%) with semaglutide 0.5 mg, and 
from –4.5 kg (baseline HbA1c >8.5–9.0%) to –6.4 kg (baseline HbA1c ≤7.5%) with 
semaglutide 1.0 mg. There was a significant effect of the HbA1c subgroup within treatment 
for both semaglutide 0.5 mg (p=0.004), and semaglutide 1.0 mg (p<0.001). The 
proportions of subjects achieving the composite endpoint (HbA1c <7.0% [<53 mmol/mol], 
without weight gain or severe/BG-confirmed symptomatic hypoglycaemia) were consistently 
lower in subgroups with higher baseline HbA1c (Supplementary Figure 1A, with ranges of 
34.5–76.2% for semaglutide 0.5 mg and 44.9–80.2% for semaglutide 1.0 mg from the 
highest to lowest baseline HbA1c subgroups.  
3.2.2 Effect by background medication (SUSTAIN 1, SUSTAIN 2–4 pooled, 
SUSTAIN 5) 
Overall, reductions in HbA1c (Figure 2A) and body weight (Figure 2B) were consistent 
across the four background antidiabetes medication subgroups (no background medication, 
metformin monotherapy, other OADs and basal insulin plus metformin), with slight 
variations in the ‘other OADs’ subgroup category for both semaglutide doses. Reductions in 
HbA1c for semaglutide 0.5 mg ranged from –1.4% (background of other OADs) to –1.6% 
(treatment-naïve), and for semaglutide 1.0 mg ranged from –1.7% (metformin 
monotherapy) to –1.9% (basal insulin ± metformin). 
Reductions in body weight for semaglutide 0.5 mg ranged from –3.4 kg (other OADs) to –
4.2 kg (treatment-naïve) and for semaglutide 1.0 mg, ranged from –4.9 kg (treatment-
naïve) to –6.5 kg (basal insulin plus metformin). 
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Due to the limitations of comparisons using pooled data and data from individual trials (as 
described in section 2.3), subgroup effects were only analysed in the background 
medication subgroups of metformin monotherapy and other OADs (SUSTAIN 2–4). There 
were no significant effects on the change from baseline in HbA1c (p=0.114) or body weight 
loss (p=0.273) for the 0.5 mg semaglutide dose. For the 1.0 mg dose, a significant 
difference was observed for body weight loss (p=0.034), but not for change from baseline in 
HbA1c (p=0.432), between metformin monotherapy and other OADs.  
The proportions of subjects achieving the composite endpoint ranged from 42.0% to 66.4% 
for semaglutide 0.5 mg and 56.8% to 69.5% for semaglutide 1.0 mg (Supplementary 
Figure 1B). The lowest proportions of subjects achieving the composite endpoint were 
observed in those receiving other OADs for both semaglutide doses. 
3.2.3 Effect by baseline diabetes duration (SUSTAIN 1–5 pooled) 
Reductions in both HbA1c (Figure 3A) and body weight (Figure 3B) were consistent, but 
with no clear pattern across the three diabetes duration subgroups (≤5, >5–10,  >10 years 
at baseline), with greater reductions observed for semaglutide 1.0 mg versus 0.5 mg. Mean 
reductions were –1.7% to –1.8% and –5.4 kg to –5.7 kg with semaglutide 1.0 mg, and –
1.4% and –3.7 kg to –3.8 kg with semaglutide 0.5 mg.  
There were no significant effects of diabetes duration for either semaglutide dose on the 
changes in HbA1c (0.5 mg: p=0.051; 1.0 mg: p=0.441) or body weight loss (0.5 mg: 
p=0.959; 1.0 mg: p=0.198)  
For semaglutide 1.0 mg, the proportions of subjects achieving the composite endpoint were 
comparable across diabetes duration subgroups (62.5–67.8%). For semaglutide 0.5 mg, the 
lowest proportion of subjects achieving the composite endpoint was observed with baseline 
diabetes duration >10 years (49.5%), compared with those with disease duration <10 years 
(≥58.7%) (Supplementary Figure 1C).  
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3.2.4 Baseline HOMA-B (SUSTAIN 1–3 pooled) 
Reductions in HbA1c were observed in all baseline HOMA-B tertiles for both semaglutide  
0.5 mg and 1.0 mg (Supplementary Figure 2A), with the magnitude of reductions 
decreasing from low to high HOMA-B tertile (ranging from –1.3% to –1.7% and from –1.5% 
to –2.0%, respectively, for each semaglutide dose). There was no significant effect of 
HOMA-B on HbA1c reductions with either semaglutide dose (0.5 mg: p=0.948;  
1.0 mg: p=0.190). 
In general, body weight was reduced in all baseline HOMA-B tertiles (Supplementary 
Figure 2B). There was no apparent difference in the reduction in body weight by tertile, 
ranging from –3.6 kg to –4.3 kg for semaglutide 0.5 mg, and from –4.9 kg to –6.1 kg for 
semaglutide 1.0 mg. The greatest reduction (–6.1 kg) was observed in the intermediate 
tertile group for semaglutide 1.0 mg; however, the effect of subgroup within treatment was 
non-significant for both semaglutide doses (0.5 mg: p=0.982; 1.0 mg: p=0.116) 
The proportions of subjects achieving the composite endpoint were similar across the 
baseline HOMA-B tertiles (Supplementary Figure 2C).  
In each of the subgroup analyses, mean HbA1c and mean body weight reductions, as well as 
the proportions of subjects achieving the composite endpoint, were greater with the higher 
dose (1.0 mg) than with the lower dose (0.5 mg) of semaglutide (Figures 1–3).  
3.3 Safety outcomes 
An overview of AEs, including gastrointestinal AEs, is presented in Table 2. For each 
semaglutide dose, the proportions of subjects reporting AEs were generally similar across 
subgroups. The proportions of subjects reporting serious AEs were greater with longer 
versus shorter duration of diabetes at baseline (Table 2) and greater in the highest 
baseline HOMA-B tertile compared with the other two tertiles for semaglutide 1.0 mg 
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(Supplementary Table 2); no trend was observed for baseline HbA1c and background 
medication subgroups. 
The proportions of subjects reporting treatment discontinuations due to AEs and 
gastrointestinal AEs were generally similar across diabetes duration subgroups (Table 2) 
and baseline HOMA-B tertiles (Supplementary Table 2), but varied with no distinctive 
pattern across baseline HbA1c and background medication subgroups. 
Overall, nausea was the most common gastrointestinal AE across all subgroups; nausea was 
highest in treatment-naïve subjects (not receiving background medication) and lowest in 
those on basal insulin ± metformin. The proportions of subjects reporting nausea were 
similar across diabetes duration subgroups with semaglutide 1.0 mg, but decreased with 
increasing diabetes duration for semaglutide 0.5 mg. There was no consistent pattern in the 
proportions of subjects reporting nausea across the baseline HbA1c subgroups and HOMA-B 
tertiles. The incidences of severe/BG glucose-confirmed hypoglycaemia were overall low and 
similar across HbA1c subgroups and diabetes duration; for background treatment, no 
incidences of hypoglycaemia were observed in treatment-naïve subjects, i.e. semaglutide 
monotherapy, while the highest rates were observed in those on a background of other 
OADs (7.1–10.0%) and basal insulin ± metformin (8.3–10.7%). 
 
4 Discussion 
Subcutaneous once-weekly semaglutide demonstrated consistently robust, clinically 
significant reductions in HbA1c and body weight in the SUSTAIN 1–5 trials.5-9 Encompassing 
patients from across the continuum of diabetes care, the SUSTAIN trials represent the 
heterogeneity of patients with T2D observed in everyday clinical practice, including wide 
ranging baseline HbA1c levels, background antidiabetes medications and diabetes 
durations.5-9 Understanding the impact these different clinical and disease characteristics 
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have on efficacy and safety of semaglutide can help clinical decision-making and 
individualization of treatment. This exploratory post hoc analysis evaluated the effect of 
semaglutide in the context of selected subgroup characteristics.  
Disease progression in diabetes is associated with worsening hyperglycaemia, indicated by 
increasing levels of HbA1c. Across the range of baseline HbA1c subgroups in this analysis, 
subjects with higher HbA1c values at baseline had the greatest reductions in HbA1c, with a 
statistically significant effect of baseline HbA1c in the semaglutide 1.0 mg treatment arm 
(p<0.05). Baseline HbA1c is a well-established predictor of glycaemic response for all 
antidiabetes treatments, even for non-pharmacological interventions;18,19 this finding is 
consistent with published findings for other GLP-1RAs, including dulaglutide,20,21 liraglutide22 
and lixisenatide.23 Importantly, from the clinical perspective, these observed differences in 
the magnitude of change from baseline in HbA1c across HbA1c subgroups resulted in a similar 
mean end-of-treatment HbA1c level. Indeed, irrespective of baseline HbA1c subgroup, HbA1c 
levels at week 30 were either close to, or less than, the ADA-recommended target of <7.0% 
(<53 mmol/mol), reflecting the glucose-dependent, antihyperglycaemic action of 
semaglutide and other GLP-1RAs.24  
The GLP-1RA class promotes weight loss,25 primarily via central, appetite-regulating 
mechanisms.24,25 Subjects with highest HbA1c at baseline lost relatively less weight than 
those with lower HbA1c at baseline, albeit with clinically relevant absolute weight loss. A 
similar pattern, with less weight loss in subjects with higher baseline HbA1c levels, was also 
observed with dulaglutide in the AWARD programme,20,21 and with liraglutide .26 These 
findings may be due to treatment-related increases in glycaemic control. In patients with 
particularly poor glycaemic control at baseline and associated caloric loss due to glucosuria, 
improving glycaemic control and reducing glucosuria may lead to mitigation of weight 
reduction.26,27 Decreased protein turnover and reduced energy expenditure with improved 
glycaemic control can also lead to weight gain.27,28 Furthermore, energy expenditure and 
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resting metabolic rate decrease with weight loss, often accompanied by increased 
appetite.27-29 Contradicting a previous suggestion that modest weight loss in subjects with 
higher HbA1c may be related to concomitant insulin treatment and accompanying insulin-
related weight gain,21 the greatest weight loss was observed in these analyses in subjects 
on a background of basal insulin ± metformin.  
GLP-1RAs, such as semaglutide, are recommended as add-on therapy to metformin and 
other OADs and as first injectable therapy in preference to insulin, unless contraindicated.1,2 
Clinically relevant reductions in HbA1c and body weight were observed in all assessed 
background medication subgroups of the SUSTAIN 1–5 trials and considerable weight loss 
was observed with semaglutide 1.0 mg, even in patients on a background of stable basal 
insulin ± metformin. The proportion of subjects achieving the composite endpoint of HbA1c 
<7.0% (53 mmol/mol), without weight gain or severe/BG-confirmed symptomatic 
hypoglycaemia has previously been reported for the SUSTAIN 1–5 trials.30 In the analysis 
presented here, the proportion of subjects achieving the triple composite endpoint was 
lowest in subjects on background medication of other OADs (including thiazolidinedione 
monotherapy, metformin plus thiazolidinedione or sulphonylurea plus thiazolidinedione), 
which may be due to preceding weight gain associated with thiazolidinediones and 
sulphonylureas,31 or to increased risk of hypoglycaemia associated with concomitant 
treatment with sulphonylureas.3  
The intensification of antidiabetes therapy required over time is considered to be an 
indicator of diabetes severity and progression, and may be closely associated with diabetes 
duration. A number of published findings for other GLP-1RAs suggest that patients with 
severe diabetes, i.e. high baseline HbA1c levels,20,32 or a shorter disease duration, e.g. less 
than 3 years,32 may particularly benefit from GLP-1RA treatment. In the analyses presented 
here, clinically relevant reductions in HbA1c and body weight were consistently observed 
even in subjects with long-standing diabetes (i.e. those with a duration of diabetes beyond 
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10 years) and the proportions of subjects achieving the triple composite endpoint were 
comparable across diabetes duration subgroups. There was a clear dose response in favour 
of semaglutide 1.0 mg versus 0.5 mg, in particular for subjects with baseline diabetes 
duration of >10 years. The hypothesized diminished insulinotropic effect of GLP-1 in long-
standing diabetes, potentially due to poor beta-cell function resulting from secondary effects 
from other hormonal, metabolic or treatment-related factors,33-36 may explain the additional 
benefits that these subjects derive from the higher dose of semaglutide maximising the 
agonistic effect of the GLP-1RA. Notable in the present analysis, despite the association of 
diabetes duration with progressively decreasing beta-cell function,37 similar reductions in 
HbA1c and body weight with semaglutide were generally observed across all levels of beta-
cell function, (assessed by HOMA-B). Consistent with previously reported semaglutide-
mediated improvements in beta-cell function and glycaemic control,38 this finding suggests 
that even in patients with low beta-cell function, clinically relevant reductions in HbA1c can 
be achieved with semaglutide treatment. 
The safety profile of semaglutide was generally similar across all subgroups, indicating no 
clear association between baseline profile and risk of AEs. Overall, semaglutide was well 
tolerated regardless of baseline HbA1c, background medication, diabetes duration or baseline 
HOMA-B, with no or low incidences of hypoglycaemia. As reported with other GLP-1RAs,39 
and for the SUSTAIN 1–5 trials,5-9 the most common AEs leading to treatment 
discontinuation with semaglutide were gastrointestinal;5-9,39 a known class effect of GLP-1RA 
therapies,40,41 these GI events typically occur during treatment initiation/escalation, but are 
transient, mild-to-moderate in severity, and diminish over time.5-9,39 In these analyses, the 
proportions of subjects reporting gastrointestinal AEs, were similar across all analysed 
subgroups. The safety findings with semaglutide are comparable to those previously 
reported for semaglutide and other GLP-1RAs.40,41 Lower rates of nausea were observed for 
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subjects on a background of basal insulin ± metformin, possibly related to compound-
specific variation inGLP-1RA-associated gastrointestinal AEs.39,40 
The strengths of these analyses include the large number of subjects in SUSTAIN 1─5 phase 
3a trials from across the continuum of T2D care, representing patients on a range of 
treatments, from drug-naïve to insulin therapy, with a broad spectrum of baseline 
characteristics. Although these analyses enable further understanding of the impact of 
clinical indicators of disease status on efficacy and safety of semaglutide across different 
trials, limitations include the nature of pooled semaglutide data, which have been analysed 
without inclusion of comparator data. As such, this is not a randomized comparison, but a 
comparison across post hoc-defined subgroups. Confounding effects from underlying 
differences, including additive effects of different background therapies, may also be 
present. Similarly, although HOMA-B analyses can be considered suitable for use in the 
presence of insulinotropic compounds,16 the data should be interpreted with caution and 
complementary to the diabetes duration subgroup analyses, as no adjustments were made 
for potential confounders, such as differences in baseline characteristics across HOMA-B 
tertiles. Furthermore, some selection bias may result from trial inclusion/exclusion criteria. 
The duration of treatment (30 weeks) examined here may not accurately reflect longer-term 
treatment but provides initial insight into treatment effects. 
In conclusion, treatment with subcutaneous once-weekly semaglutide was consistently 
efficacious, reducing HbA1c and body weight to a clinically important extent, across 
subgroups by disease severity and progression in subjects with uncontrolled T2D. 
Semaglutide was well-tolerated, with a low risk of hypoglycaemia, across the continuum of 
diabetes care and a broad range of clinical characteristics. These analyses show that efficacy 
and safety of semaglutide is preserved, regardless of these patient characteristics and 
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Table 1. Trial designs and baseline characteristics of subjects receiving semaglutide (SUSTAIN 1–5)5-9 
Trial SUSTAIN 1 SUSTAIN 2 SUSTAIN 3 SUSTAIN 4 SUSTAIN 5 
Semaglutide 0.5 mg/1.0 mg 0.5 mg/1.0 mg 1.0 mg 0.5 mg/1.0 mg 0.5 mg/1.0 mg 
Comparator Placebo Sitagliptin  
100 mg 
Exenatide ER  
2.0 mg 
Insulin glargine Placebo  
(add-on to basal insulin) 
Trial duration 30 weeks 56 weeks 56 weeks 30 weeks 30 weeks 




Open-label Open-label Double-blind,  
placebo-controlled 
Previous therapy Drug-naïve OAD OAD OAD Insulin ± MET 
Therapy type Monotherapy Add-on: 
MET ± TZD, 
Add-on: 1–2 OADs 
(MET ± TZD ± SU) 
Add-on:  
MET ± SU 
Add-on:  
basal insulin ± MET 
Semaglutide  0.5 mg 1.0 mg 0.5 mg 1.0 mg 1.0 mg 0.5 mg 1.0 mg 0.5 mg 1.0 mg 
Subjects, n 128 130 409 409 404 362 360 132 131 
Age, years 54.6 ±  11.1 52.7 ± 11.9 54.8 ± 10.2 56.0 ± 9.4 56.4 ± 10.3 56.5 ± 10.3 56.7 ± 10.4 59.1 ± 10.3 58.5 ± 9.0 
Male, % 47 62 51 50 54 54 51 56 59 
Body weight, kg 89.8 ± 23.0 96.9 ± 25.6 89.9 ± 20.4 89.2 ± 20.7 96.2 ± 22.5 93.7 ± 21.4 94.0 ± 22.5 92.7 ± 19.6 92.5 ± 22.2 
BMI, kg/m2 32.5 ± 7.6 33.9 ± 8.4 32.4 ± 6.2 32.5 ± 6.6 34.0 ± 7.2 33.1 ± 6.5 33.0 ± 6.5 32.8 ± 6.0 32.0 ± 6.4 
HbA1c, % 8.1 ± 0.9 8.1 ± 0.8 8.0 ± 0.9 8.0 ± 0.9 8.4 ± 0.9 8.1 ± 0.8 8.3 ± 0.9 8.4 ± 0.8 8.3 ± 0.8 
Diabetes duration, 
years 
4.8 ± 6.1 3.6 ± 4.9 6.4 ± 4.7 6.7 ± 5.6 9.0 ± 6.0 7.8 ± 5.1 9.3 ± 7.2 12.9 ± 7.6 13.7 ± 7.8 
HOMA-B, %a 39.7 ± 118.8 43.3 ± 114.4 32.8 ± 93.6 33.7 ± 98.1 39.0 ± 97.2 - - - - 
Data were sourced from original trial reports if not publicly available. Data are means, or mean ± standard deviation, unless otherwise stated. aHOMA-B data 
are geometric mean ± coefficient of variation and were evaluated in SUSTAIN 1, 2 and 3 only. BMI, body mass index; exenatide ER, exenatide extended-
release; HOMA-B, homeostatic model assessment of beta-cell function; MET, metformin; OAD, oral antidiabetes drug; RCT randomized controlled trial; SU, 




Table 2. Adverse events by subgroup (SUSTAIN 1–5)  
 





HbA1c, % ≤7.5 >7.5–8.0 >8.0–8.5 >8.5–9.0 >9.0 ≤7.5 >7.5–8.0 >8.0–8.5 >8.5–9.0 >9.0 
HbA1c, mmol/mol ≤58 >58–64 >64–69 >69–75 >75 ≤58 >58–64 >64–69 >69–75 >75 
n  332 216 178 134 171 409 300 250 179 296 
Total AEs (any grade) 240 (72.3) 155 (71.7) 124 (69.6) 93 (69.7) 120 (70.6) 302 (73.8) 202 (67.9) 172 (68.7) 125 (70.2) 215 (72.6) 
Serious AEs 19 (5.7) 16 (7.4) 12 (6.8) 8 (5.9) 12 (7.1) 30 (7.2) 19 (6.5) 21 (8.5) 16 (9.1) 18 (6.2) 




25 (7.5) 12 (5.7) 7 (3.9) 12 (9.3) 11 (6.4) 43 (10.4) 26 (8.8) 16 (6.6) 15 (8.5) 19 (6.4) 
Gastrointestinal AEs 133 (40.1) 88 (40.4) 69 (38.8) 51 (39.3) 71 (41.7) 186 (45.5) 116 (39.0) 88 (35.1) 76 (42.0) 117 (39.2) 
Nausea 63 (19.0) 41 (18.7) 26 (14.6) 29 (22.1) 32 (18.7) 101 (24.8) 63 (21.0) 40 (16.0) 34 (18.0) 57 (18.9) 
Diarrhoea 35 (10.6) 32 (14.7) 26 (14.7) 22 (17.2) 20 (11.8) 51 (12.6) 43 (14.5) 30 (12.0) 25 (13.8) 42 (14.0) 
Vomiting 23 (6.9) 12 (5.7) 10 (5.6) 12 (9.2) 13 (7.8) 44 (10.8) 21 (7.1) 18 (7.2) 20 (11.3) 28 (9.3) 
Severe or blood 
glucose-confirmed 
hypoglycaemia 















n  128 559 212 132   130 775 398 131 
Total AEs (any grade) 82 (64.1) 413 (73.9) 146 (68.8) 91 (68.9)   73 (56.2) 559 (72.1) 300 (75.5) 84 (64.1) 
Serious AEs 7 (5.5) 41 (7.3) 11 (5.2) 8 (6.1)   7 (5.4) 63 (8.1) 22 (5.5) 12 (9.2) 
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8 (6.3) 44 (7.9) 9 (4.2) 6 (4.5)   7 (5.4) 70 (9.0) 34 (8.6) 8 (6.1) 
Gastrointestinal AEs 49 (38.3)  238 (42.6) 89 (41.8) 23 (17.4)   50 (38.5) 314 (40.6) 174 (43.9) 37 (28.2) 
Nausea 26 (20.3) 108 (19.3) 42 (19.8) 15 (11.4)   31 (23.8) 164 (21.2) 78 (19.7) 22 (16.8) 
Diarrhoea 16 (12.5) 77 (13.8) 36 (16.9) 6 (4.5)   14 (10.8) 98 (12.7) 70 (17.6) 9 (6.9) 
Vomiting 5 (3.9) 46 (8.2) 11 (5.2) 8 (6.1)   9 (6.9) 69 (8.9) 38 (9.6) 15 (11.5) 
Severe or blood 
glucose-confirmed 
hypoglycaemia 
0 (0) 8 (1.4) 15 (7.1) 11 (8.3)   0 (0) 11 (1.4) 40 (10.0) 14 (10.7) 
Diabetes duration, 
years 
 ≤5 >5–10 >10   ≤5 >5–10 >10  
n   420 322 289   519 462 453  
Total AEs (any grade)  301 (71.5) 226 (70.4) 205 (70.9)   360 (69.6) 319 (68.9) 337 (74.6)  
Serious AEs  27 (6.4) 17 (5.3) 23 (7.9)   31 (5.9) 37 (8.0) 36 (8.1)  




 26 (6.3) 21 (6.5) 20 (7.1)   41 (7.8) 38 (8.2) 40 (8.9)  
Gastrointestinal AEs  179 (42.4) 126 (39.4) 107 (37.2)   205 (39.6) 174 (37.6) 204 (45.6)  
Nausea  86 (20.5) 59 (18.6) 46 (15.9)   106 (20.4) 96 (20.7) 93 (20.8)  
Diarrhoea  56 (13.3) 40 (12.5) 39 (13.9)   70 (13.5) 64 (13.9) 57 (12.5)  
Vomiting  31 (7.3) 17 (5.3) 22 (7.5)   46 (8.9) 40 (8.7) 45 (9.9)  
Severe or blood 
glucose-confirmed 
hypoglycaemia 
 11 (2.5) 4 (1.2) 19 (6.7)   14 (2.8) 20 (4.4) 31 (6.8)  
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aOther OADs included TZD monotherapy, MET+TZD or SU+TZD. Severe or blood glucose-confirmed hypoglycaemia was defined as an episode that was severe 
according to the ADA classification or blood glucose-confirmed by a plasma glucose value below 3.1 mmol/L (56 mg/dL) with symptoms consistent with 
hypoglycaemia. %, proportion of subjects experiencing at least one event; ADA, American Diabetes Association; AE, adverse event; MET, metformin; n, 






Figure 1. Efficacy endpoints at week 30 by baseline HbA1c subgroups (≤7.5%, >7.5–8.0%, 
>8.0–8.5%, >8.5–9.0%, and >9.0%): (A) change from baseline in HbA1c and (B) change 
from baseline in body weight. 
Data shown are mean ± SEM for the categories analysed. Subgroups are categorized as ≤7.5% [≤58 mmol/mol]; 
>7.5–8.0% [>58–64 mmol/mol], >8.0–8.5% [>64–69 mmol/mol], >8.5–9.0% [>69–75 mmol/mol] and >9.0% 
[>75 mmol/mol]. Estimated changes are based on pooled data from the SUSTAIN 1–5 trials. BG, blood glucose; 
BW, body weight; SEM, standard error of the mean.  
 
Figure 2. Efficacy endpoints at week 30 by background medication subgroups (no 
background medication [SUSTAIN 1], metformin monotherapy [pooled data from SUSTAIN 
2–4], other oral antidiabetes therapy [pooled data from SUSTAIN 2–4] and basal insulin 
plus metformin [SUSTAIN 5]): (A) change from baseline in HbA1c and (B) change from 
baseline in body weight.  
Data shown are mean ± SEM for the categories analysed. Estimated changes are based on data from the SUSTAIN 
1–5 trials, with analyses performed on SUSTAIN 2–4 collectively, but individually for SUSTAIN 1 and 5, so that p-
values are provided only for the comparison of metformin monotherapy and other OADs. BG, blood glucose; BW, 
body weight; OAD, oral antidiabetes drug; SEM, standard error of the mean. 
 
Figure 3. Efficacy endpoints at week 30 by diabetes duration subgroups (≤5 years, >5–10 
years and >10 years): (A) change from baseline in HbA1c and (B) change from baseline in 
body weight.  
Data shown are mean ± SEM for the categories analysed. Estimated changes are based on pooled data from the 
SUSTAIN 1–5 trials. BG, blood glucose; BW, body weight; SEM, standard error of the mean.  
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Figure 3. Diabetes duration subgroups 
 
 
 
 
 
